Intercambiar Beldex BDX a Transfidelity FIDEL

Beldex building a decentralized confidential ecosystem in Web3 for secure digital interactions.. The concept of the project was developed in 2018, and launched in the same year. The Beldex project is committed to enhancing user data protection and their confidentiality online. BDX is an ecosystem coin that facilitates confidential transactions. Beldex's mission is to provide a confidential environment where data can be exchanged securely. The project is focused on individual safety and true data confidentiality with systematic research to ensure the confidentiality of individual transactions, and thus the safety of users and the security of their funds. BDX operates on the Beldex decentralized blockchain for performing secure transactions, while the ecosystem supports secure and confidential dApps, among them: BChat, BelNet, Beldex Browser, the Beldex protocol, and the Beldex bridge. Initially, Beldex was developed on a PoW architecture followed by a transition to the PoS consensus model in order to increase the scalability of the BDX token, lower fees and reduce transaction times.

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.